Description
Cell and tissue therapies are about to revolutionize the treatment of a number of diseases, including: organ, replacement, cartilage, skin, autoimmune diseases, diabetes, neurodegenerative diseases, cancer and cardiovascular tissue damage. Although cell therapy is not a new phenomenon, what is new is the scope and versatility of research using stem cell and tissue therapeutics, and products based on combinations of cell therapy, gene manipulation, and tissue engineering.
The report provides world market projections 2002-2007, discusses market trends and issues including how bioethics debates are affecting development and what the best marketing models for these new therapies will be. The report also makes considered predictions about the companies and technologies to watch as the cell therapy industry evolves.
Table of Contents
Chapter One: Executive Summary
- Scope and Methodology
- Size and Growth of the Market
- Market Trends
Chapter Two: Introduction
- Cell Therapy—Past, Present, and Future
- A Word About Stem Cells
- Disease Opportunities and Scientific Reticence
- Point of View
Chapter Three: Cell Technology Commercialization: The Journey from Bench to Clinic
- Problems with Embryonic Stem Cells: It’s More than Ethics
- Adult Stem Cells to the Rescue?
- Autologous, Allogeneic, and Xenogenic Products
- Cell Therapy Equipment and Accessories
- Cloning and Bioengineering Cells and Tissues
- The Journey Continues
Chapter Four: Market Trends and Issues
Population Demographics and The Demand for Cell and Tissue Products
- Patent Issues
- Technology and Reimbursement Issues
- New Technology Commercialization
- Regulatory Affairs
- The European Union
- Germany
- France
- Spain
- United Kingdom
- Sweden
- Japan
- China
- Singapore
- Israel
- Canada
- Australia
- United States
Chapter Five: Cell Therapy Applications: Commercial and Non-Commercial Research
- Cancer Vaccines
- Cardiovascular Diseases
- Diabetes
- Electronic Tissue
- Gene / Drug Delivery
- Immune System Modulation
- Nervous System Injuries / Neurological Diseases
- Organ Replacement / Tissue Engineering
- Miscellaneous Applications
Chapter Six: Market Analysis
- Introduction
- Bioengineered Skin Products
- Bone and Cartilage
- Stem Cell Therapy, 2002-2007
- Cell therapy, 2005-2015
- Company Mergers and Closures
- Cell Cloning
Chapter Seven: Conclusions and Strategic Implications
- First Conclusion
- Implication
- Second Conclusion
- Implication
- Third Conclusion
- Implication
- Fourth Conclusion
- Implication
- Fifth Conclusion
- Implication
Chapter Eight: Companies and Technologies To Watch
Chapter Nine: Company Profiles
- Aastrom Biosciences, Inc.
- Advanced Cell Technology (ACT)
- AmCyte Inc.
- Anthrogenesis (Acquired by Celgene Corp.)
- Artecel Inc. (formerly Artecel Sciences, Inc.)
- Athersys Inc.
- Baxter Healthcare Corporation
- Bioheart Inc.
- BresaGen Ltd.
- Celgene Corporation
- Cell Transplants International, LLC (CTI)
- Celmed BioSciences Inc.
- Chromos Molecular Systems Inc.
- Diatranz, Ltd.
- ES Cell International Pte Ltd (ESI)
- Gamida-Cell Ltd.
- GenVec Inc. / Diacrin
- Geron Corporation
- Immuno-Designed Molecules S.A. (IDM)
- Kourion Therapeutics
- LifeCell Corporation
- Merix Bioscience, Inc.
- MicroIslet Inc.
- Nucleotech LLC
- Osiris Therapeutics Inc.
- Proneuron Biotechnologies Inc.
- Transition Therapeutics Inc.
- ViaCell, Inc.
- Xcyte Therapies, Inc
Appendix A: List of Cell Therapy Companies and Their Products
Appendix B: Lexicon of Cell Therapy Terms
List of Exhibits
Chapter Three: Cell Technology Commercialization: The Journey from Bench to Clinic
- Table 3-1: Providers of Currently Approved Cell Lines
- Table 3-2: Selected Companies Working on Adult and Stem Cell Therapies
- Table 3-3: Selected Cell Encapsulated Cell Therapeutics
- Table 3-4: Selected Cell Therapy Products using Xenogenic Cells
- Table 3-5: Selected Cell Therapy Equipment and Accessories
- Table 3-6: Selected Cell and Tissue Bioengineered Products
Chapter Five: Cell Therapy Applications: Commercial and Non-Commercial Research
- Table 5-1: Selected Cancer Vaccine Programs
- Table 5-2: Selected Stem Cell Therapies for Cardiovascular Disease
- Table 5-3: Selected Diabetes Cell Therapy Products
- Table 5-4: Selected Neural Stem Cell Therapies
- Table 5-5: Selected Organ Bioengineering Programs
Chapter Six: Market Analysis
- Table 6-1: Number of Patients in Selected Cell Therapy Target Populations in the United States
- Table 6-2: Worldwide Market for Selected Cell Therapies by Type 2002-2007
- Table 6-3: Sales of the Leading Skin Replacement Products 2002
- Table 6-4: Cell Replacement Procedures by Region 2002-2007
- Figure 6-1: Technology Penetration Forecast for Cell Therapy Technologies
Chapter Eight: Companies and Technologies to Watch
- Table 8-1: Strength Analysis of 22 Selected Cell Therapy Companies
- Table 8-2: Kalorama’s Short List of Cell Therapy Companies
